Lv11
10 积分 2024-06-22 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4小时前
待确认
PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
9小时前
求助中
Site-Specific Mutagenesis Screening in KRASG12D Mutant Library to Uncover Resistance Mechanisms to KRASG12D Inhibitors
5天前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
7天前
已完结
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
8天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
8天前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
8天前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
8天前
已完结
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
8天前
已完结
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations
15天前
已完结
皖公网安备34019202002308
